Sanuwave Health Shares Crater Following Revenue Guidance Cut

Chief Executive Morgan Frank attributed the downward revision to volatile conditions within the capital equipment market for the company’s UltraMIST wound-healing system. While the business showed signs of early-year recovery, momentum stalled between May and June. Frank pointed to aggressive clawbacks of CMS reimbursements for skin sub and allograft usage as a primary catalyst for the downturn, noting that these financial pressures are forcing numerous wound care practices to shutter operations.

The resulting market instability has created a secondary issue for Sanuwave: a surplus of used UltraMIST systems flooding the market as failing practices liquidate their assets. This influx of pre-owned equipment is actively cannibalizing demand for new units. With shares already down 68% year-to-date, this latest guidance adjustment underscores the deepening headwinds facing the company's core commercial strategy.